Visionary Pharmaceuticals is a leading biotechnology company dedicated to changing the world by stopping autoimmune diseases and cancer. They are focused on developing first-in-class drugs to address the unmet medical needs in these areas. Their drug discovery portfolio includes RORγt and SGK1, which are important targets in both autoimmune diseases and cancer.

RORγt is targeted at over 70 autoimmune diseases, including inflammatory bowel disease, arthritis, multiple sclerosis, and psoriasis. It is also a novel target for colorectal cancer. SGK1, on the other hand, plays a critical role in chemoresistance, tumor growth, and invasiveness in multiple cancers, with a particular focus on triple-negative breast cancer.

Visionary Pharmaceuticals is driven by a mission to develop innovative drugs and utilizes a proprietary game-changing technology platform for rapid, efficient, and cost-effective hit finding and lead optimization. They have an exceptional Nuclear Receptor and Kinase Knowledge Engine that speeds up the development of oral therapeutics with high ligand efficiency. With their passion, technical excellence, and cutting-edge science, Visionary Pharmaceuticals is committed to permanently changing the world by transforming the treatment of autoimmune diseases and cancer